Failing to conduct comprehensive screening for strain selection and media development at the project's start creates issues that become significantly more difficult and expensive to resolve later. Small, early-stage problems can derail downstream processing and scale-up efforts entirely.

While transient plant expression offers unprecedented speed for biologics production, it lacks a traditional Master Cell Bank. This introduces a unique regulatory challenge: batch-to-batch consistency is not guaranteed by a clonal cell line but depends on managing variables like plant growth and Agrobacterium infiltration efficiency.

The traditional goal of isolating a single, perfect clone is misleading. Biology's inherent variability means even the first cell division introduces differences. A more effective approach is to assess a cell population's performance distribution (e.g., productivity, growth) to gauge its robustness and predictability over many generations.

Many teams focus on optimizing the main bioreactor when reproducibility issues arise. However, the root cause is often an inconsistent pre-culture. Switching transfer criteria from manual sampling (like optical density) to a reliable online signal like Oxygen Transfer Rate (OTR) can solve this issue.

Many assume genetically modifying Mesenchymal Stem Cells (MSCs) is the main technical hurdle. The greater challenge is developing a robust, reproducible manufacturing process that delivers a functionally equivalent product every time, despite inherent variability from donors and process steps.

Downstream purification processes can be modified and optimized throughout a product's lifecycle. However, the cell line selection is effectively permanent once the master cell bank is created. Choosing a non-robust cell line, such as one highly sensitive to minor pH shifts, will create persistent manufacturing challenges for the lifetime of the product.

Contrary to the belief of those outside manufacturing, establishing a bioprocess is not a one-time task. The inherent unpredictability of biology means things will inevitably go wrong even in the most controlled environments, making it a continuous and difficult challenge.

For live cell therapies, the manufacturing process fundamentally shapes the biological product. Teams often rush to scale production, focusing on yield and cost. Instead, they should first fully understand how the process impacts cell potency and function to avoid effectively scaling the wrong biology.

Early CMC decisions for Phase 1 clinical supply are foundational. Certain errors made at this stage, such as failing to prove cell bank clonality, are irreversible and can jeopardize the entire development program, similar to a faulty foundation in a house.